Engineering a Single-Chain Fv Antibody to αvβ6 Integrin Using the Specificity-Determining Loop of a Foot-and-Mouth Disease Virus

Journal of Molecular Biology

Volumn 382, Issue 2, 2008, Pages 385-401

  Kogelberg, Heide ^a   Tolner, Berend ^a   Thomas, Gareth J ^b   Di Cara, Danielle ^b   Minogue, Shane ^c   Ramesh, Bala ^c   Sodha, Serena ^a   Marsh, Dan ^a   Lowdell, Mark W ^a   Meyer, Tim ^a   Begent, Richard H J ^a   Hart, Ian ^b   Marshall, John F ^b   Chester, Kerry ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

antibody engineering; foot and mouse disease virus; integrin v 6; scFv; VP1 peptide

Indexed keywords

ALPHAVBETA6 INTEGRIN; CARCINOEMBRYONIC ANTIBODY; CARCINOEMBRYONIC ANTIGEN; PROTEIN MFE23; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS PROTEIN 1;

ANTIBODY ENGINEERING; ANTIBODY SPECIFICITY; ARTICLE; CELL ADHESION; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; FOOT AND MOUTH DISEASE VIRUS; HUMAN; HUMAN CELL; PICHIA PASTORIS; POINT MUTATION; PRIORITY JOURNAL; RECEPTOR BINDING;

FOOT-AND-MOUTH DISEASE VIRUS; MURINAE; PICHIA PASTORIS;

EID: 50249174510     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2008.07.013     Document Type: Article

References (51)

1. Hynes R.O. Integrins: bidirectional, allosteric signaling machines. Cell 110 (2002) 673-687
2. Breuss J.M., Gallo J., DeLisser H.M., Klimanskaya I.V., Folkesson H.G., Pittet J.F., et al. Expression of the beta 6 integrin subunit in development, neoplasia and tissue repair suggests a role in epithelial remodeling. J. Cell Sci. 108 (1995) 2241-2251
3. Ruoslahti E. Integrins. J. Clin. Invest. 87 (1991) 1-5
4. Giancotti F.G., and Mainiero F. Integrin-mediated adhesion and signaling in tumorigenesis. Biochim. Biophys. Acta 1198 (1994) 47-64
5. Thomas G.J., Nystrom M.L., and Marshall J.F. Alphavbeta6 integrin in wound healing and cancer of the oral cavity. J. Oral Pathol. Med. 35 (2006) 1-10
6. Arihiro K., Kaneko M., Fujii S., Inai K., and Yokosaki Y. Significance of alpha 9 beta 1 and alpha v beta 6 integrin expression in breast carcinoma. Breast Cancer 7 (2000) 19-26
7. Sipos B., Hahn D., Carceller A., Piulats J., Hedderich J., Kalthoff H., et al. Immunohistochemical screening for beta6-integrin subunit expression in adenocarcinomas using a novel monoclonal antibody reveals strong up-regulation in pancreatic ductal adenocarcinomas in vivo and in vitro. Histopathology 45 (2004) 226-236
8. Ahmed N., Pansino F., Clyde R., Murthi P., Quinn M.A., Rice G.E., et al. Overexpression of alpha(v)beta6 integrin in serous epithelial ovarian cancer regulates extracellular matrix degradation via the plasminogen activation cascade. Carcinogenesis 23 (2002) 237-244
9. Munger J.S., Huang X., Kawakatsu H., Griffiths M.J., Dalton S.L., Wu J., et al. The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell 96 (1999) 319-328
10. Bates R.C., Bellovin D.I., Brown C., Maynard E., Wu B., Kawakatsu H., et al. Transcriptional activation of integrin beta6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma. J. Clin. Invest. 115 (2005) 339-347
11. Hazelbag S., Kenter G.G., Gorter A., Dreef E.J., Koopman L.A., Violette S.M., et al. Overexpression of the alpha v beta 6 integrin in cervical squamous cell carcinoma is a prognostic factor for decreased survival. J. Pathol. 212 (2007) 316-324
12. Elayadi A.N., Samli K.N., Prudkin L., Liu Y.H., Bian A., Xie X.J., et al. A peptide selected by biopanning identifies the integrin alphavbeta6 as a prognostic biomarker for nonsmall cell lung cancer. Cancer Res. 67 (2007) 5889-5895
13. Ramos D.M., But M., Regezi J., Schmidt B.L., Atakilit A., Dang D., et al. Expression of integrin β6 enhances invasive behavior in oral squamous cell carcinoma. Matrix Biol. 21 (2002) 297-307
14. Adams G.P., and Weiner L.M. Monoclonal antibody therapy of cancer. Nat. Biotechnol. 23 (2005) 1147-1157
15. Holliger P., and Hudson P.J. Engineered antibody fragments and the rise of single domains. Nat. Biotechnol. 23 (2005) 1126-1136
16. Wu A.M., and Senter P.D. Arming antibodies: prospects and challenges for immunoconjugates. Nat. Biotechnol. 23 (2005) 1137-1146
17. Logan D., Abu-Ghazaleh R., Blakemore W., Curry S., Jackson T., King A., et al. Structure of a major immunogenic site on foot-and-mouth disease virus. Nature 362 (1993) 566-568
18. Monaghan P., Gold S., Simpson J., Zhang Z., Weinreb P.H., Violette S.M., et al. The alpha(v)beta6 integrin receptor for foot-and-mouth disease virus is expressed constitutively on the epithelial cells targeted in cattle. J. Gen. Virol. 86 (2005) 2769-2780
19. Brown J.K., McAleese S.M., Thornton E.M., Pate J.A., Schock A., Macrae A.I., et al. Integrin-alphavbeta6, a putative receptor for foot-and-mouth disease virus, is constitutively expressed in ruminant airways. J. Histochem. Cytochem. 54 (2006) 807-816
20. Jackson T., King A.M., Stuart D.I., and Fry E. Structure and receptor binding. Virus Res. 91 (2003) 33-46
21. Burman A., Clark S., Abrescia N.G., Fry E.E., Stuart D.I., and Jackson T. Specificity of the VP1 GH loop of foot-and-mouth disease virus for αv integrins. J. Virol. 80 (2006) 9798-9810
22. Ludbrook S.B., Barry S.T., Delves C.J., and Horgan C.M. The integrin alphavbeta3 is a receptor for the latency-associated peptides of transforming growth factors beta1 and beta3. Biochem. J. 369 (2003) 311-318
23. Duque H., LaRocco M., Golde W.T., and Baxt B. Interactions of foot-and-mouth disease virus with soluble bovine alphavbeta3 and alphavbeta6 integrins. J. Virol. 78 (2004) 9773-9781
24. Dicara D., Rapisarda C., Sutclifffe J.L., Violette S.M., Weinreb P.H., Hart I.R., et al. Structure-function analysis of RGD-helix motifs in αvβ6 integrin ligands. J. Biol. Chem. 282 (2007) 9657-9665
25. Boehm M.K., Corper A.L., Wan T., Sohi M.K., Sutton B.J., Thornton J.D., et al. Crystal structure of the anti-(carcinoembryonic antigen) single-chain Fv antibody MFE-23 and a model for antigen binding based on intermolecular contacts. Biochem. J. 346 (2000) 519-528
26. Chester K.A., Begent R.H., Robson L., Keep P., Pedley R.B., Boden J.A., et al. Phage libraries for generation of clinically useful antibodies. Lancet 343 (1994) 455-456
27. Begent R.H., Verhaar M.J., Chester K.A., Casey J.L., Green A.J., Napier M.P., et al. Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library. Nat. Med. 2 (1996) 979-984
28. Mayer A., Tsiompanou E., O'Malley D., Boxer G.M., Bhatia J., Flynn A.A., et al. Radioimmunoguided surgery in colorectal cancer using a genetically engineered anti-CEA single-chain Fv antibody. Clin. Cancer Res. 6 (2000) 1711-1719
29. Chester K.A., Bhatia J., Boxer G., Cooke S.P., Flynn A.A., Huhalov A., et al. Clinical applications of phage-derived sFvs and sFv fusion proteins. Dis. Markers 16 (2000) 53-62
30. Chester K.A., Mayer A., Bhatia J., Robson L., Spencer D.I., Cooke S.P., et al. Recombinant anti-carcinoembryonic antigen antibodies for targeting cancer. Cancer Chemother. Pharmacol. 46 (2000) S8-S12
31. Read D.A., Chester K.A., Keep P.A., Begent R.H.J., Pedersen J.T., and Rees A.R. Mutagenesis of single-chain antibody MFE 23 and its effect on affinity for CEA. Br. J. Cancer 71 (1995) 57
32. Thomas G.J., Hart I.R., Speight P.M., and Marshall J.F. Binding of TGF-beta1 latency-associated peptide (LAP) to alpha(v)beta6 integrin modulates behaviour of squamous carcinoma cells. Br. J. Cancer 87 (2002) 859-867
33. Lee Y.C., Boehm M.K., Chester K.A., Begent R.H., and Perkins S.J. Reversible dimer formation and stability of the anti-tumour single-chain Fv antibody MFE-23 by neutron scattering, analytical ultracentrifugation, and NMR and FT-IR spectroscopy. J. Mol. Biol. 320 (2002) 107-127
34. Graff C.P., Chester K., Begent R., and Wittrup K.D. Directed evolution of an anti-carcinoembryonic antigen scFv with a 4-day monovalent dissociation half-time at 37 degrees C. Protein Eng. Des. Sel. 17 (2004) 293-304
35. Jackson T., Sheppard D., Denyer M., Blakemore W., and King A.M. The epithelial integrin alphavbeta6 is a receptor for foot-and-mouth disease virus. J. Virol. 74 (2000) 4949-4956
36. Boehm M.K., and Perkins S.J. Structural models for carcinoembryonic antigen and its complex with the single-chain Fv antibody molecule MFE23. FEBS Lett. 475 (2000) 11-16
37. Frederickson S., Renshaw M.W., Lin B., Smith L.M., Calveley P., Springhorn J.P., et al. A rationally designed agonist antibody fragment that functionally mimics thrombopoietin. Proc. Natl Acad. Sci. USA 103 (2006) 14307-14312
38. Kohler G., and Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256 (1975) 495-497
39. Winter G., Griffiths A.D., Hawkins R.E., and Hoogenboom H.R. Making antibodies by phage display technology. Annu. Rev. Immunol. 12 (1994) 433-455
40. McLane K.E., Burton D.R., and Ghazal P. Transplantation of a 17-amino acid alpha-helical DNA-binding domain into an antibody molecule confers sequence-dependent DNA recognition. Proc. Natl Acad. Sci. USA 92 (1995) 5214-5218
41. Sc. Proc. Natl Acad. Sci. USA 101 (2004) 10404-10409
42. Qin W., Feng J., Li Y., Lin Z., and Shen B. A novel domain antibody rationally designed against TNF-alpha using variable region of human heavy chain antibody as scaffolds to display antagonistic peptides. Mol. Immunol. 44 (2007) 2355-2361
43. Main A.L., Harvey T.S., Baron M., Boyd J., and Campbell I.D. The three-dimensional structure of the tenth type III module of fibronectin: an insight into RGD-mediated interactions. Cell 71 (1992) 671-678
44. Lanza P., Felding-Habermann B., Ruggeri Z.M., Zanetti M., and Billetta R. Selective interaction of a conformationally-constrained Arg-Gly-Asp (RGD) motif with the integrin receptor alphavbeta3 expressed on human tumor cells. Blood Cells, Mol. Dis. 23 (1997) 230-241
45. Lanza P., Billetta R., Antonenko S., and Zanetti M. Active immunity against the CD4 receptor by using an antibody antigenized with residues 41-55 of the first extracellular domain. Proc. Natl Acad. Sci. USA 90 (1993) 11683-11687
46. Hoogenboom H.R. Selecting and screening recombinant antibody libraries. Nat. Biotechnol. 23 (2005) 1105-1116
47. Thomas G.J., Lewis M.P., Whawell S.A., Russell A., Sheppard D., Hart I.R., et al. Expression of the alphavbeta6 integrin promotes migration and invasion in squamous carcinoma cells. J. Invest. Dermatol. 117 (2001) 67-73
48. Hawkins R.E., Zhu D., Ovecka M., Winter G., Hamblin T.J., Long A., and Stevenson F.K. Idiotypic vaccination against human B-cell lymphoma. Rescue of variable region gene sequences from biopsy material for assembly as single-chain Fv personal vaccines. Blood 83 (1994) 3279-3288
49. Tolner B., Smith L., Begent R.H., and Chester K.A. Production of recombinant protein in Pichia pastoris by fermentation. Nat. Protoc. 1 (2006) 1006-1021
50. Tolner B., Smith L., Begent R.H., and Chester K.A. Expanded-bed adsorption immobilized-metal affinity chromatography. Nat. Protoc. 1 (2006) 1213-1222
51. Weinacker A., Chen A., Agrez M., Cone R.I., Nishimura S., Wayner E., et al. Role of the integrin alpha v beta 6 in cell attachment to fibronectin. Heterologous expression of intact and secreted forms of the receptor. J. Biol. Chem. 269 (1994) 6940-6948